ABSTRACT
Background and Aims Topiramate is widely prescribed to treat a variety of conditions, including alcohol use disorder (AUD). We used electronic health record (EHR) data to examine topiramate’s effects on drinking in individuals differentiated by a history of AUD.
Design Parallel-groups comparison of patients prescribed topiramate and a propensity-score matched comparison group.
Setting A large U.S. integrated healthcare system.
Participants Patients with Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) scores prior to and after a minimum of 180 days of topiramate prescription for any indication and a propensity-score matched group. The sample included 5,918 patients with an electronic health record diagnosis of alcohol use disorder at any time (AUD-hx-pos) (1,738 topiramate exposed and 4,180 controls) and 23,614 patients with no EHR diagnosis of AUD (AUD-hx-neg) (6,324 topiramate exposed and 17,290 controls).
Measurements Regression analyses compared difference-in-difference (DiD) estimates, separately by AUD history. DiD estimates represent exposure-group (i.e., topiramate vs. control) differences on the pre-post difference in AUDIT-C score. Effects of baseline AUDIT-C score and daily topiramate dosage were also tested.
Findings Among AUD-hx-neg patients, those who received topiramate had a greater reduction in AUDIT-C score (−0.11) than matched controls (−0.04). This yielded a DiD score of -0.07 (95% CI= -0.11,-0.03; P =0.002), with the greatest effect among AUD-hx-neg patients with a baseline AUDIT-C score of 4+ (DiD = -0.35, 95% CI=-0.49, -0.21; P <0.0001) and those prescribed >150 mg/day of the medication (DiD = -0.15, 95%CI=-0.23, -0.07; P <0.001).
Discussion The lack of an effect of topiramate on drinking levels in AUD-hx-pos patients contrasts with the robust reductions seen in topiramate clinical trials. Research is needed to ascertain whether AUDIT-C scores from EHR data accurately reflect medication effects on drinking and whether patient characteristics can be used to select patients most likely to reduce their drinking when treated with topiramate.
Competing Interest Statement
Dr. Kranzler is an advisory board member for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals and Enthion Pharmaceuticals. He is a consultant for Sobrera Pharmaceuticals and a recipient from Alkermes of funds and study medication for investigator-initiated research. Dr. Kranzler is a member of the American Society of Clinical Psychopharmacology Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. Dr. Kranzler holds U.S. patent #10,900,082 titled: "Genotype-guided dosing of opioid agonists,” issued 26 January 2021.
Funding Statement
This study was funded by the Mental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4, Crescenz Veterans Affairs Medical Center
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board, Crescenz VAMC, Philadelphia, PA
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing Interests: Dr. Kranzler is an advisory board member for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant for Sobrera Pharmaceuticals; a recipient from Alkermes of funds and study medication for investigator-initiated research; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka; and is named as an inventor on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. The other authors have no disclosures to make.
Data Availability
All data produced in the present study are available upon reasonable request to the authors, within the constraints of the Department of Veterans Affairs regulations.
